Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mometasone Furoate for Otitis Media With Effusion
NCT03491098Phase 1Unknown
- Start
- May 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, single-blind trial of mometasone furoate nasal spray in otitis media with effusion (OME) (3 arms). Primary endpoints: Hearing loss at 8 weeks, Nasal obstruction at 8 weeks and 1 more. Status: unknown.
02
Drugs
mometasone furoate nasal spray
03
Conditions
otitis media with effusion (OME)
Beyond the preview
Go deeper on NCT03491098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491098.